Test Code: 30141
Cpt Code:83520 (x1)
For the quantitative measurement of Elafin. Elafin, a protein expressed by keratinocytes within the epidermis of the skin, has been shown to be elevated in medical conditions where immune dysregulation occurs causing damage of the skin.
The assay for quantification of Elafin is a sandwich ELISA performed in a microtiter plate format. Conversion of a chromogenic substrate produces a color, the intensity of which is proportional to the concentration of Elafin in the sample material. A standard curve is used to calculate the concentration of Elafin in each of the test samples. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
Specific to human Elafin.
The result is reported in ng/mL. The assay range is approximately 1.3 to 80 ng/mL. The reference range for a healthy population is less than 24.0 ng/mL. However it should be noted that these ranges are obtained from a limited population of apparently healthy adults and are not diagnostic thresholds.
Causes For Rejection
Invalid specimen type, inadequate volume, gross hemolysis or gross lipemia, sample not frozen upon receipt.
Test performed M,W,F. TAT 3 - 5 days from receipt of specimen.
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. A Viracor-IBT test requisition form must accompany each specimen. Multiple tests can be run on one specimen. Ship specimens FedEx Priority Overnight® to: Viracor-IBT Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086.
NY approved. Whole blood should be collected in sodium heparin tubes and plasma separated by centrifugation within 30 minutes of the draw time. 1 mL of plasma sample should be removed to a sterile tube and frozen immediately (-70°C).
Specimens are approved for testing in New York only when indicated in the Specimen Information field above.
The CPT codes provided are based on Viracor-IBT's interpretation of the American Medical Association's Current Procedural Terminology (CPT) codes and are provided for general informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. Viracor-IBT assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material.
Alam SR, Newby DE, Henriksen PA. Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury from epithelium to endothelium. Biochem Pharmacol. 2012 83:695-704.
Shaw L, Wiedow O. Therapeutic potential of human elafin. Biochem Soc Trans. 2011 39(5):1450-1454.
Aung G, Niyonsaba F, Ushio H, et al. Elafin and secretory leukocyte protease inhibitor stimulate the production of cytokines and chemokines by human keratinocytes via MAPK/ERK and NF-kB activation. J Dermatol Sci. 2011 63:122-131.
Zani M-L, Tanga A, Saidi A, et al. SLPI and trappin-2 as therapeutic agents to target airway serine proteases in inflammatory lung diseases: current and future directions. Biochem Soc Trans. 2011 39:1441-1446
Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft versus host disease of the skin. Sci Transl Med. 2010 2:50-57.